How I Found Support While Facing a Rare Cancer Diagnosis Alone
I was facing rare mesothelioma alone at 21 years old, but sharing my story connected me to a community that offers hope and strength to keep fighting.
Related Articles
Individual and Organisational Factors Influencing Turnover Intention Among Clinical Nurses: A Cross‐Sectional Secondary Analysis
Background Turnover intention among nurses is a well-established predictor of actual turnover. Despite the critical nursing shortages during COVID-19, the relative contributions of individual and…
Why It’s Important to Know That “Lung Cancer Can Affect Everybody”
In an interview with CURE, medical oncologist Dr. Ioana Bonta explains why lung cancer is not just a ‘smoker’s disease.’
Expanding Clinical Trial Access for Patients With Cancer
It is vital that clinical trials for patients with cancer shift to a more representative approach to accurately reflect real-world patient populations.
Your Story Isn’t Over Start Each Day With Hope and Purpose
I’m a testicular cancer survivor diagnosed at 20. My story is about finding strength, building routines, and sharing hope for those facing cancer.
Relief and Confidence After Biology-Guided Radiation for Breast Cancer
A nurse with metastatic breast cancer praised biology-guided radiation for her slow-growing squamous cell cancer and the team’s thoughtful care.
Pelabresib Plus Rituxan Elicits Meaningful Responses in Myelofibrosis
Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed.
How Do Childhood Cancer Treatments Accelerate Biological Aging?
Childhood cancer treatments can accelerate biological aging which increases survivors’ risk for long-term health issues like heart disease and obesity.
AACN-Gold Interprofessional Humanism in Healthcare Award – The Arnold P. Gold Foundation
The Arnold P. Gold Foundation and the American Association of Colleges of Nursing (AACN) seek nominations for the AACN-Gold Interprofessional Humanism in Healthcare Award, a…
FDA Accepts NDA for Vepdegestrant in ESR1+ Advanced Breast Cancer
The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, review date.